Why this industry behaves differently
Anvisa classifies medical devices into risk classes I–IV; classes I–II use notification while classes III–IV require marketing authorization under the current framework.
E2M RESEARCH · INDUSTRY GUIDES
HEALTH → BR
Healthcare & Medical Devices → Brazil
Healthcare entry is regulatory-first and channel-specific. A strong product does not become commercially available until the authorization, local responsible party/import path, evidence, buyer workflow and after-sales model fit Brazil.
Market structure
Market structure
Private hospital groups, labs, clinics, distributors, health networks and public procurement coexist. Product type determines whether the commercial path is direct, distributor-led, tender-led or tied to clinical/technical adoption.
Buyer map
- hospital procurement and clinical engineering
- physicians / clinical champions where relevant
- laboratory / diagnostic networks
- specialized distributors and public buyers
Regulatory gate
Start with Anvisa classification and authorization pathway, Brazilian registration/holder responsibilities, importer structure, labeling/instructions and any local technical-responsibility requirement. Pharmaceuticals and other health products have different regimes and should be scoped separately.
GTM motion
Regulatory readiness and clinical/technical evidence precede scale. Build reference sites, KOL/clinical champions where appropriate, distributor capability and a support/training model; do not treat Brazil as pure e-commerce.
Common entry patterns
- specialized distributor / registration holder
- direct strategic-account development + licensed local partner
- local applications/clinical support hire
- entity when contracting, inventory or regulatory ownership justifies it
Talent & local capabilities
Regulatory affairs, clinical/application specialists, hospital sales and distributor management are high-leverage. Product training and Portuguese technical materials are essential.
Operating considerations
- map registration/notification before launch budget
- define complaint/vigilance and support processes
- verify import storage and traceability needs
- model tender/payment cycles separately from private sales
90 DAYS
First 90-day moves
0–30classify the exact product and authorization path
31–60interview 8–10 hospital/distributor stakeholders
61–90build a reference-site and channel shortlist
Primary sources to validate
This guide is market-entry intelligence, not legal, tax, regulatory, clinical, engineering or professional advice. Product, licensing and sector obligations must be validated for the exact offering and operating model before execution.
Medical Devices Regulation
Anvisa · Validated 24 Sep 2026
Related E2M resources
Brazil Market Entry →GTM / Business Development →Hiring / Talent →City Intelligence →Expansion Sourcebook →First 90 Days →
Operating boundary. This guide is market-entry intelligence, not legal, tax, regulatory, clinical, engineering or professional advice. Product, licensing and sector obligations must be validated for the exact offering and operating model before execution.
Brazil market entry for medical devices and healthcare suppliers
Explore a sector-specific route →Start my 90-second assessment →A promising distributor is not enough if regulatory ownership, clinical demand and procurement pathways remain unclear.
What buyers must establish before choosing a partner
A trade agreement or origin country only matters after demand, viable margin, compliance and channel responsibilities have been tested. Public expansion examples illustrate different entry models, not a guarantee that the same model suits your company.